Pilatus doses first patient in Phase I PLT012 trial for HCC

​

Pilatus Biosciences has dosed the first patient in Hong Kong, as part of an ongoing Phase I clinical trial assessing PLT012, an investigational therapy for HCC.

The post Pilatus doses first patient in Phase I PLT012 trial for HCC appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.